

## Controlled Release

International Edition: DOI: 10.1002/anie.201900850  
German Edition: DOI: 10.1002/ange.201900850

## Organelle-Targeted BODIPY Photocages: Visible-Light-Mediated Subcellular Photorelease

Dnyaneshwar Kand, Lorena Pizarro, Inbar Angel, Adi Avni, Dinorah Friedmann-Morvinski, and Roy Weinstein\*

**Abstract:** Photocaging facilitates non-invasive and precise spatio-temporal control over the release of biologically relevant small- and macro-molecules using light. However, subcellular organelles are dispersed in cells in a manner that renders selective light-irradiation of a complete organelle impractical. Organelle-specific photocages could provide a powerful method for releasing bioactive molecules in subcellular locations. Herein, we report a general post-synthetic method for the chemical functionalization and further conjugation of meso-methyl BODIPY photocages and the synthesis of endoplasmic reticulum (ER)-, lysosome-, and mitochondria-targeted derivatives. We also demonstrate that 2,4-dinitrophenol, a mitochondrial uncoupler, and puromycin, a protein biosynthesis inhibitor, can be selectively photo-released in mitochondria and ER, respectively, in live cells by using visible light. Additionally, photocaging is shown to lead to higher efficacy of the released molecules, probably owing to a localized and abrupt release.

The interior of cells is a highly organized environment. Cellular tasks such as energy production, protein synthesis, and many others, are functionally compartmentalized in organelles, along with most of the biomolecules required for their execution. Studying localized processes, including those taking place inside organelles, often makes use of small-molecules to manipulate their progress.<sup>[1]</sup> Unfortunately, most small-molecules lack an innate specificity for cellular locations; they tend to disperse randomly in cells, not necessarily arriving at the desired place owing to unsuitable physical-chemical properties or conversely, ending up in too many locations in an unspecific manner.

Photocaging<sup>[2]</sup> is an effective light-mediated controlled-release strategy that enables activation of small- or macro-bioactive molecules with high spatio-temporal resolution.<sup>[3]</sup> This strategy is widely utilized to achieve localized control over the activation of bioactive molecules in vitro and in vivo.<sup>[4]</sup> However, organelles are scattered or dispersed in cells in a manner that renders selective irradiation of a complete organelle (e.g., mitochondria or golgi apparatus) impractical, undermining the utility of the strategy in this context. Over the years, several chemical motifs have been determined to passively accumulate in specific sub-cellular compartments owing to their chemical and/or physical properties (e.g., pH, charge, and hydrophobicity). Such motifs include, for example, triphenylphosphonium<sup>[5]</sup> (TPP), phenyl sulfonamide,<sup>[6]</sup> and tertiary/secondary amines<sup>[7]</sup> that tend to accumulate in mitochondria, endoplasmic reticulum (ER), and lysosomes/endosomes, respectively. Their coupling to small- and even macro-molecules was found to effectively impart sub-cellular specificity to the entire conjugate.


The combination of sub-cellular targeting with photocaging, providing a means of preserving the advantages of the two strategies while overcoming their distinct limitations, has been effectively demonstrated using 2-nitrobenzyl derivatives caging groups.<sup>[8]</sup> However, the use of UV-excitable photocages often leads to inherent hurdles, including sample overheating and phototoxicity. More recent work has effectively improved the utility of targeted photocages by using coumarins, excitable at around 400 nm, as caging groups.<sup>[9]</sup>

Herein, we establish a range of organelle-targeted photocages based on the recently introduced, visible-light excitable (> 500 nm) meso-methyl BODIPY photocage<sup>[10]</sup> (Figure 1).

[\*] Dr. D. Kand, Dr. L. Pizarro, Prof. Dr. A. Avni, Dr. R. Weinstein  
School of Plant Sciences and Food Security, Life Sciences Faculty, Tel-Aviv University  
Tel-Aviv 6997801 (Israel)  
E-mail: royweinstein@tauex.tau.ac.il  
I. Angel, Dr. D. Friedmann-Morvinski  
School of Neurobiology, Biochemistry and Biophysics, Life Sciences Faculty, Tel-Aviv University  
Tel-Aviv 6997801 (Israel)

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:  
<https://doi.org/10.1002/anie.201900850>.

© 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.




**Figure 1.** Schematic of ER-, lysosome-, and mitochondria-targeted BODIPY photocages.

To this end, we also developed a straightforward, post-synthetic method for the functionalization of BODIPYs that streamlines their synthesis.

The photoreaction efficiency in BODIPY photocages,<sup>[10d]</sup> as well as in many other photocaging groups,<sup>[11]</sup> is highly sensitive to changes in electronic and steric properties of the core. We therefore first sought to establish a robust synthetic approach for chemical functionalization of BODIPY photocages without affecting their photorelease ability.

The synthetic procedure is outlined in Figure 2A. Using a one-pot, two-step protocol, that is, bromination with *N*-bromosuccinimide (NBS) followed by nucleophilic substitution, compounds **1–5** were synthesized. This is a modified



**Figure 2.** A) Synthetic scheme of compounds **1–5**. B) Synthetic scheme of organelle-targeting compounds **11–13**.


approach to an earlier report,<sup>[12]</sup> which leverages the nucleophilic character of BODIPY  $\alpha$ -methyls to introduce bromine as a leaving group. In this case, the superior nucleophilicity of thiols is employed to introduce less nucleophilic yet reactive functional groups through appropriate bifunctional molecules. Thus, various unprotected functional groups including amine, thiol, chloro, carboxylic acid, and azide groups, all key building blocks in the construction of more elaborate molecules, could be simply and directly introduced. We verified that the reactive functionalities installed can be further conjugated in the context of BODIPY photocages by reacting each of them in a compatible manner (i.e., amidation, Michael addition to *N*-ethyl maleimide, and copper-mediated click reaction) (compounds **6–10**, Figure S1).

The photophysical and photoreaction properties of all synthesized compounds are summarized in Tables S1. Compared to previously reported BODIPY photocages,<sup>[10a,b,d]</sup> all new derivatives (**1–10**) present a 5–7 nm red-shift in both absorbance and fluorescence  $\lambda_{\text{max}}$ , with molar extinction coefficient values in the typical BODIPY range (ca. 35 000–70 000 M<sup>-1</sup> cm<sup>-1</sup>). Photoreaction properties were determined by UV/Vis spectroscopy, monitoring *p*-nitroaniline (PNA) release (see Supporting Information). Compounds **5–8** and **10** are stable in the absence of light but release PNA in response to irradiation with visible light (545/30 nm, 42 mW cm<sup>-2</sup>), presenting comparable photoreaction properties (quantum yield ( $\Phi_f$ ), half-life ( $t_{1/2}$ ), and chemical yield) to previously


reported BODIPY photocages (Table S1, Figure S2). These results confirm that the above-described post-synthetic methodology can be straightforwardly applied to conjugate BODIPY photocages through diverse chemical functionalities while retaining their spectroscopic and photoreaction properties.

We next applied the synthetic approach to generate a panel of organelle-targeted BODIPY photocages. A direct HBTU-mediated coupling of compound **4** with different amine-bearing organelle-directing groups such as phenyl sulfonamide (ER targeting), morpholine (lysosome targeting), and TPP (mitochondria targeting), afforded targeted BODIPY photocages **11–13**, respectively (Figure 2B). Compounds **11–13** are stable in the absence of light and show controlled release of PNA upon irradiation with visible light (Table S1 and Figure S3). Their cellular uptake and sub-cellular localization were evaluated in HeLa cells by live-cell imaging using commercial stains for ER, lysosomes, and mitochondria (Figures 3 and Figures S9 and S10). All three compounds demonstrated efficient localization to their target organelles as determined by Pearson's sample correlation coefficients ( $r=0.95$ , 0.73, and 0.75 for **11**, **12**, and **13**, respectively) with the respective organelles stains (ER-tracker Blue, LysoTracker deep-red, and MitoTracker deep-red).

To evaluate the utility of organelle-targeted BODIPY photocages, we synthesized and tested a caged version of the protonophore 2,4-dinitrophenol (DNP). DNP is an uncoupler of mitochondrial oxidative phosphorylation, dissipating the proton gradient across the membrane thus decreasing mitochondrial membrane potential<sup>[13]</sup> ( $\Delta\psi_m$ ). Compound **14** was synthesized by *ipso*-substitution of 1-fluoro-2,4-dinitroben-



**Figure 3.** Cellular distribution and co-localization of compounds **11–13**. Confocal fluorescence images of live HeLa cells incubated with a–c) ER-Tracker Blue (2  $\mu\text{M}$ ) and **11** (10  $\mu\text{M}$ , 30 min), d–f) LysoTracker deep-red (2  $\mu\text{M}$ ) and **12** (10  $\mu\text{M}$ , 30 min), g–i) MitoTracker deep-red (2  $\mu\text{M}$ ) and **13** (10  $\mu\text{M}$ , 30 min). Co-localization appears as yellow/orange (c), (f), (i).



**Figure 4.** A) Structures of compounds **14** and **16**. B) Light-mediated release of DNP from **14** and **16** (10  $\mu\text{M}$ , ACN/water 7:3) following light irradiation (545/30 nm, 42  $\text{mWcm}^{-2}$ ) for the indicated times. Absorbance at 367 nm (representing free DNP) vs. time was plotted. C) Distribution and co-localization of **14** and **16**. Confocal images of live HeLa cells treated with Hoechst 33342 (17  $\mu\text{M}$ ), MitoTracker deep-red (2  $\mu\text{M}$ ) and **14** (upper) or **16** (lower) (10  $\mu\text{M}$ , 30 min). Areas of co-localization appear in yellow/orange in Merged. D) Photorelease of DNP in live cells leads to decrease in mitochondrial membrane potential. Confocal images of live HeLa cells stained with Hoechst 33342 (17  $\mu\text{M}$ ) and Rhod123 (26  $\mu\text{M}$ , 15 min), a,e) in the absence of light at  $t=0$  and 5 min; b,f) before and after treatment with 200  $\mu\text{M}$  DNP; c,g) compound **14** (25  $\mu\text{M}$ ) with and without light (545/25 nm, 1.4  $\text{mWcm}^{-2}$ , 15 s); d,h) compound **16** (25  $\mu\text{M}$ ) with and without light (545/25 nm, 1.4  $\text{mWcm}^{-2}$ , 15 s). E) Decrease in cells fluorescence intensity, where  $F_0$  is fluorescence intensity before either light or DNP treatment and  $F$  is fluorescence intensity after either light or DNP treatment. F,G) Localized photoactivation of DNP in live cells. HeLa cells were incubated with Rho123 (26  $\mu\text{M}$ ), **16** (25  $\mu\text{M}$ ), and Hoechst 33342 (17  $\mu\text{M}$ ) for 15 min before (F) and after (G) light irradiation (545/25 nm, 1.4  $\text{mWcm}^{-2}$ , 15 s) of a selected region. H) Fold-decrease in fluorescence intensity of cells in irradiated and non-irradiated regions, where  $F_0$  and  $F$  are defined as in (E). \* Statistical significance (one-way ANOVA with Tukey correction,  $p < 0.05$ ) from control (E) or non-irradiated cells (H). Error bars show the standard error (SE).

zene with *meso*-methyl BODIPY and functionalized by employing the above-described protocol using thioglycolic acid as a nucleophile. A TPP motif was subsequently coupled to obtain the mitochondria-targeted BODIPY-DNP **16** (Figures 4A and Figure S4). Quantum yields, half-lives ( $t_{1/2}$ ), and chemical yields for photorelease of DNP were determined by UV/Vis spectroscopy and confirmed by HPLC-MS. Compounds **14** and **16** are stable in the dark and release DNP when irradiated with visible light (Figures 4B and Figures S5 and S6), compound **16** presenting the highest photorelease efficiency ( $\epsilon\Phi_r=43$ ) within this series of compounds (Table S1). Although BODIPY photocages were previously demonstrated to release halides, acids, carbon monoxide, thiols, and xanthates,<sup>[10]</sup> this is first example of direct uncaging of phenols, expanding the palette of functional groups and bioactive molecules amenable for caging by BODIPYs.

Cellular uptake and mitochondrial localization of **16** were examined and compared to the non-targeted **14** by live-cell imaging of HeLa cells (Figures 4C and Figures S9 and S11). Low Pearson's sample correlation coefficients ( $r=0.13$ ) confirmed poor targeting of **14** to the mitochondria while **16** showed efficient and specific mitochondrial accumulation ( $r=0.84$ ).

Next, intracellular photoactivation of **16** was investigated. Changes in  $\Delta\psi_m$  were assessed using the  $\Delta\psi_m$ -sensitive lipophilic cationic dye, rhodamine 123 (Rho123). In intact

cells, Rho123 accumulates in mitochondria, leading to a strong localized fluorescence signal.<sup>[14]</sup> Conversely, reduction in  $\Delta\psi_m$  leads to redistribution of the dye to the cytoplasm, resulting in its dilution and a decrease in fluorescence signal. In HeLa cells treated with Rho123, strong mitochondrial fluorescence could be detected, which was significantly reduced (ca. 3-fold) by further treatment with 200  $\mu\text{M}$  DNP (Figure 4D and Figure S12). When similar cells were treated with Rho123 and **16** (25  $\mu\text{M}$ ), a mitochondria-localized fluorescence signal was observed, indicating that **16** by itself does not disrupt  $\Delta\psi_m$ . However, upon irradiation of the cells (545/25 nm, 1.4  $\text{mWcm}^{-2}$ , 15 s), a 6-fold decrease in Rho123 mitochondrial fluorescence was observed. Importantly, photoactivation of the non-targeted **14** under similar conditions did not have any effect on Rho123 fluorescence. Cells treated with Rho123 alone and exposed to similar irradiation conditions did not show any change in mitochondrial fluorescence, ruling out direct light effect on  $\Delta\psi_m$ . In addition, in the absence of light, **16** did not show any sign of toxicity at the applied concentration (Figure S14).

Finally, we tested light-mediated selective activation of **16** in specific cells. Thus, HeLa cells were treated with Rho123, **16**, and the DNA stain Hoechst 33342, and confocal images were acquired at three channels (Figure 4F and Figure S13 a). Cells were then irradiated for 15 s (545/25 nm, 1.4  $\text{mWcm}^{-2}$ ) in a selected region (marked by a yellow rectangle) and re-



imaged after 5 min (Figure 4G and Figure S13b). Results show a significant (ca. 13-fold) decrease in fluorescence signal only in cells within the light-exposed region while cells outside of it remains unaffected. Quantification of the averaged fluorescence intensities of cells within the irradiated area versus those outside of it, before and after light exposure, is shown in Figure 4H.

To demonstrate the general applicability of BODIPY photocages targeting, we synthesized an ER-targeted caged version of the protein synthesis inhibitor puromycin<sup>[15]</sup> (**19**, Figure S15). Compound **19** showed efficient light-dependent release of puromycin in vitro and in HeLa cells (Figure S15B) and colocalized efficiently with ER-tracker blue ( $r=0.95$ , Figure S16C). Following photoactivation of **19** in live cells (20  $\mu\text{M}$ , 545/305 nm, 42  $\text{mW cm}^{-2}$ ), released puromycin could be detected specifically in the ER, unlike treatment with free puromycin that was detected throughout the cell (ER, cytoplasm, nucleus), as visualized by immunostaining (Figure S16E).

In summary, we developed a set of BODIPY photocages suitable for visible-light-mediated release of bioactive molecules in specific, pre-designated organelles. We have established a post-synthetic procedure to straightforwardly introduce conjugatable functional groups onto BODIPY  $\alpha$ -methyl in one synthetic step and without compromising their spectroscopic nor photoreaction properties. This procedure represents a unique post-synthetic functionalization method applicable to BODIPYs at large, providing a simple and effective solution to the traditional challenge of BODIPY functionalization, usually requiring multi-step processes.<sup>[16]</sup> Thus, it not only should provide access to conjugation of BODIPY photocages to other small- or macro-molecules but also uniquely represents a simple path to direct activation and further (bio-)conjugation of BODIPYs when used as fluorescent tags. The developed procedure was applied to generate a set of organelle-targeted BODIPY photocages in a divergent manner. All organelle-targeted BODIPY photocages efficiently localized to their pre-designated sub-cellular compartments. A mitochondria-targeted BODIPY was demonstrated to release the protonophore DNP in live cells with exquisite spatio-temporal control, achieving a much higher effect compared to non-targeted DNP. Thus, photocaging introduces spatio-temporal specificity to organelle targeting and leads to higher efficacy of the bioactive molecule, most probably owing to localized and abrupt release. Finally, we expect that our approach could be extended to the selective delivery of a wide range of bioactive molecules to diverse organelles in order to perturb and study their localized processes and functions. The use of BODIPY provides access to photoactivation with biologically benign visible light thus eliminating concerns of phototoxicity associated with traditional UV-excitable photocages and, potentially, opening the way to organelle-targeted light-mediated drug delivery.

### Acknowledgements

W.R. would like to thank the United States-Israel Binational Science Foundation (Grant No. 2016060), the Germany-Israel

Foundation (Grant No. I-2387-302.5/2015) and the ERC (Grant No. 679189), and D.F.M. to the Israeli Science Foundation (1310/15), for funding this research. D.K. thanks the Planning and Budgeting Committee (PBC) of the Israeli Council for Higher Education for a postdoctoral fellowship. We would like to thank Prof. Evan W. Miller (UC Berkeley) for helpful discussions.

### Conflict of interest

The authors declare no conflict of interest.

**Keywords:** BODIPY · mitochondria · organelles · photocages · photo-release

**How to cite:** *Angew. Chem. Int. Ed.* **2019**, *58*, 4659–4663  
*Angew. Chem.* **2019**, *131*, 4707–4711

- [1] a) D. J. Maly, F. R. Papa, *Nat. Chem. Biol.* **2014**, *10*, 892–901; b) S. Piao, R. K. Amaravadi, *Ann. N. Y. Acad. Sci.* **2016**, *1371*, 45–54; c) N. M. Sakhrani, H. Padh, *Drug Des. Dev. Ther.* **2013**, *7*, 585–599; d) S. E. Weinberg, N. S. Chandel, *Nat. Chem. Biol.* **2015**, *11*, 9–15.
- [2] J. H. Kaplan, B. Forbush 3rd, J. F. Hoffman, *Biochemistry* **1978**, *17*, 1929–1935.
- [3] a) C. W. Riggsbee, A. Deiters, *Trends Biotechnol.* **2010**, *28*, 468–475; b) Q. Shao, B. Xing, *Chem. Soc. Rev.* **2010**, *39*, 2835–2846.
- [4] a) L. Fournier, C. Gauron, L. Xu, I. Aujard, T. Le Saux, N. Gagey-Eilstein, S. Maurin, S. Dubrulle, J. B. Baudin, D. Bensimon, M. Volovitch, S. Vriza, L. Jullien, *ACS Chem. Biol.* **2013**, *8*, 1528–1536; b) R. R. Nani, A. P. Gorka, T. Nagaya, H. Kobayashi, M. J. Schnermann, *Angew. Chem. Int. Ed.* **2015**, *54*, 13635–13638; *Angew. Chem.* **2015**, *127*, 13839–13842.
- [5] a) A. T. Hoye, J. E. Davoren, P. Wipf, M. P. Fink, V. E. Kagan, *Acc. Chem. Res.* **2008**, *41*, 87–97; b) S. Wisnovsky, E. K. Lei, S. R. Jean, S. O. Kelley, *Cell Chem. Biol.* **2016**, *23*, 917–927.
- [6] a) H. Xiao, P. Li, X. Hu, X. Shi, W. Zhang, B. Tang, *Chem. Sci.* **2016**, *7*, 6153–6159; b) H. Xiao, X. Liu, C. Wu, Y. Wu, P. Li, X. Guo, B. Tang, *Biosens. Bioelectron.* **2017**, *91*, 449–455.
- [7] a) C. A. Goodman, P. Pierre, T. A. Hornberger, *Proc. Natl. Acad. Sci. USA* **2012**, *109*, E989; author reply E990; b) T. Liu, Z. Xu, D. R. Spring, J. Cui, *Org. Lett.* **2013**, *15*, 2310–2313.
- [8] a) S. Chalmers, S. T. Caldwell, C. Quin, T. A. Prime, A. M. James, A. G. Cairns, M. P. Murphy, J. G. McCarron, R. C. Hartley, *J. Am. Chem. Soc.* **2012**, *134*, 758–761; b) A. Leonidova, V. Pierroz, R. Rubbiani, Y. J. Lan, A. G. Schmitz, A. Kaech, R. K. O. Sigel, S. Ferrari, G. Gasser, *Chem. Sci.* **2014**, *5*, 4044–4056.
- [9] a) A. Nadler, D. A. Yushchenko, R. Muller, F. Stein, S. Feng, C. Mülle, M. Carta, C. Schultz, *Nat. Commun.* **2015**, *6*, 10056; b) N. Wagner, M. Stephan, D. Hoglinger, A. Nadler, *Angew. Chem. Int. Ed.* **2018**, *57*, 13339–13343; *Angew. Chem.* **2018**, *130*, 13523–13527; c) S. Feng, T. Harayama, S. Montessuit, F. P. David, N. Winssinger, J. C. Martinou, H. Riezman, *eLife* **2018**, *7*, 1–23.
- [10] a) P. P. Goswami, A. Syed, C. L. Beck, T. R. Albright, K. M. Mahoney, R. Unash, E. A. Smith, A. H. Winter, *J. Am. Chem. Soc.* **2015**, *137*, 3783–3786; b) N. Rubinstein, P. Liu, E. W. Miller, R. Weinstain, *Chem. Commun.* **2015**, *51*, 6369–6372; c) K. Sitkowska, B. L. Feringa, W. Szymanski, *J. Org. Chem.* **2018**, *83*, 1819–1827; d) T. Slanina, P. Shrestha, E. Palao, D. Kand, J. A. Peterson, A. S. Dutton, N. Rubinstein, R. Weinstain, A. H. Winter, P. Klan, *J. Am. Chem. Soc.* **2017**, *139*, 15168–15175.

- [11] P. Klán, T. Šolomek, C. G. Bochet, A. Blanc, R. Givens, M. Rubina, V. Popik, A. Kostikov, J. Wirz, *Chem. Rev.* **2013**, *113*, 119–191.
- [12] G. Ulrich, R. Ziessel, A. Haefele, *J. Org. Chem.* **2012**, *77*, 4298–4311.
- [13] a) J. E. Bestman, K. D. Stackley, J. J. Rahn, T. J. Williamson, S. S. Chan, *Differentiation* **2015**, *89*, 51–69; b) G. B. Pinchot, *J. Biol. Chem.* **1967**, *242*, 4577–4583.
- [14] a) G. Annamalai, S. Kathiresan, N. Kannappan, *Biomed. Pharmacother.* **2016**, *82*, 226–236; b) G. Duan, S. Hou, J. Ji, B. Deng, *Cancer Biomarkers* **2018**, *22*, 29–34; c) Y. Y. Lu, T. S. Chen, J. L. Qu, W. L. Pan, L. Sun, X. B. Wei, *J. Biomed. Sci.* **2009**, *16*, 16.
- [15] a) F. Buhr, J. Kohl-Landgraf, S. tom Dieck, C. Hanus, D. Chatterjee, A. Hegelein, E. M. Schuman, J. Wachtveitl, H. Schwalbe, *Angew. Chem. Int. Ed.* **2015**, *54*, 3717–3721; *Angew. Chem.* **2015**, *127*, 3788–3792; b) I. Elamri, M. Heumuller, L. M. Herzig, E. Stirnal, J. Wachtveitl, E. M. Schuman, H. Schwalbe, *ChemBioChem* **2018**, *19*, 2458–2464; c) L. M. Herzig, I. Elamri, H. Schwalbe, J. Wachtveitl, *Phys. Chem. Chem. Phys.* **2017**, *19*, 14835–14844; d) J. Kohl-Landgraf, F. Buhr, D. Lefrancois, J. M. Mewes, H. Schwalbe, A. Dreuw, J. Wachtveitl, *J. Am. Chem. Soc.* **2014**, *136*, 3430–3438.
- [16] a) N. Boens, B. Verbelen, W. Dehaen, *Eur. J. Org. Chem.* **2015**, 6577–6595; b) A. Loudet, K. Burgess, *Chem. Rev.* **2007**, *107*, 4891–4932; c) H. Wang, F. R. Fronczek, M. G. Vicente, K. M. Smith, *J. Org. Chem.* **2014**, *79*, 10342–10352.

Manuscript received: January 22, 2019

Accepted manuscript online: February 7, 2019

Version of record online: February 28, 2019